exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087879 RNA Name: hsa-miR-199b-5p RNA Type: miRNA Chromosome: chr9 Starnd: - Coordinate: Start Site(bp): 128244783 End Site(bp): 128244805 External Links: hsa-miR-199b-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand ALDH3B2 chr11 67662160 67681224 - ATP9A chr20 51596514 51768390 - CHD2 chr15 92900189 93027996 + COL4A2 chr13 110305812 110513209 + COX6A1 chr12 120438090 120440737 + FAM222B chr17 28755978 28855232 - FOSL2 chr2 28392448 28417317 + HMGCS1 chr5 43287470 43313512 - KRT80 chr12 52168996 52192014 - MYRF chr11 61752642 61788518 + NFE2L1 chr17 48048329 48061545 + SLC7A5 chr16 87830023 87869507 - WNT5A chr3 55465715 55490539 - XPO6 chr16 28097979 28211920 - ZMIZ1 chr10 79068966 79316528 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000591 chr15 41961025 41962156 + hsa_circ_0001005 chr2 53921020 53978078 - hsa_circ_0000892 chr19 11941431 12014514 + hsa_circ_0000931 chr19 38226804 38231095 - lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC004951.4 chr7 43951910 44019151 - AC095055.1 chr4 151139991 151141103 + BX284668.2 chr1 16870945 16883659 + LINC01783 chr1 16533886 16536172 - POLR2J4 chr7 43940895 44019175 - SNHG12 chr1 28578538 28583132 - TMPO-AS1 chr12 98512973 98516422 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.